Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
收藏Mendeley Data2026-04-18 收录
官方服务：
资源简介：
A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
MERIBEL研究：一项针对经紫杉类药物预处理的侵袭性人表皮生长因子受体2（HER2）阴性转移性乳腺癌患者，采用艾立布林作为一线治疗方案的II期多中心单臂临床试验
创建时间：
2019-01-09
